Effect of antihypertensive drug classes in metabolic syndrome

Background: Metabolic syndrome (MetS) affects approximately 35% of the adult population of United States as well as categorized by the synchronized existence of hypertension, hyperglycemia, obesity and dyslipidemia.  Now a days, this is the main cause of leading CVD (cardiovascular disease) risk in an individual. Raised blood pressure is the record common component of this syndrome and this incidence increases with age.
Objective: This research was carried out to recommend the characterizations for the metabolic syndrome along with the occurrence of hypertension in this disorder. Additionally, indications concerning the properties of metabolic of the diverse antihypertensive drug modules and their consequence on metabolic syndrome will be demonstrated.
Methods: A comprehensive trial in different patients were performed to identify data from clinical investigations for the occurrence, patho-physiology and treatment of hypertension in MetS.
Results: Hypertension existing in almost 79% Pakistani patients alon with metabolic syndrome. The usage of thiazide diuretics, and beta-blockers salts, is dejected in the present community; though, latest signs recommend its use under precise circumstances. The Ca. channel inhibitors appear to apply a unbiased outcome on Metabolic syndrome. Whereas, renin angiotensin scheme inhibitors are supposed to be of the utmost advantage. Even though, variances occur among various agents of this class.
Conclusion: Debate still exists about the ideal anti-hypertensive treatment in Metabolic syndrome. Due to the huge occurrence of hypertension in Pakistani community, still, further investigations and data is in dire need for this treatment.